Core Viewpoint - Izotropic Corporation held its Annual General and Special Meeting on December 29, 2025, where key corporate matters were approved by shareholders [1][2]. Group 1: Meeting Outcomes - All nominees for the board of directors were approved, maintaining the number of directors at five [3]. - The re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP was approved [3]. - An amendment to the Company's By-Laws was made to reduce the quorum requirement from 20% to at least 1% of the issued voting shares, while decisions will still require majority approval. This change addresses challenges faced by public companies, such as mail delays and disruptions in receiving voting packages [3]. Group 2: Shareholder Engagement - The Company expressed gratitude to all shareholders for their participation and ongoing support [4]. Group 3: Company Information - Izotropic Corporation focuses on innovative medical technologies and imaging products for breast cancer screening, diagnosis, and treatment [1]. - Additional information about the Company can be found on its corporate website and educational platform [5].
Izotropic Announces AGM Results
TMX Newsfile·2025-12-31 21:31